Structured evidence table for Akkermansia Muciniphila Supplement, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Akkermansia Muciniphila Supplement | 1 2 3 4 5 The global burden of type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) continues to rise at an alarming pace. | 3 | Dinkov Boris (2026) | Akkermansia muciniphila and GLP-1-Based Therapies: Bidirectional Interactions and Implications for Type 2 Diabetes and MASLD/MASH |
| Akkermansia Muciniphila Supplement | MASLD may progress to metabolic dysfunction-associated steatohepatitis (MASH), characterized by hepatocellular injury, lobular inflammation, and fibrosis, which significantly increases the risk of cirrhosis and hepatocellular carcinoma []. | 3 | Dinkov Boris (2026) | Akkermansia muciniphila and GLP-1-Based Therapies: Bidirectional Interactions and Implications for Type 2 Diabetes and MASLD/MASH |
| Akkermansia Muciniphila Supplement | A growing body of preclinical and clinical evidence indicates that GLP-1-based therapies exert significant modulatory effects on the composition and function of the gut microbiome, which may indirectly contribute to their hepatoprotective properties. | 3 | Dinkov Boris (2026) | Akkermansia muciniphila and GLP-1-Based Therapies: Bidirectional Interactions and Implications for Type 2 Diabetes and MASLD/MASH |
| Akkermansia Muciniphila Supplement | Current estimates indicate that approximately 589 million people worldwide are living with diabetes, with T2DM accounting for over 90% of cases []. | 3 | Dinkov Boris (2026) | Akkermansia muciniphila and GLP-1-Based Therapies: Bidirectional Interactions and Implications for Type 2 Diabetes and MASLD/MASH |
| Akkermansia Muciniphila Supplement | According to the Global Burden of Disease study, the incidence of such disorders has increased in recent decades, particularly in developed nations (;). | 3 | Xie Luyu (2026) | Mechanism and application of Akkermansia muciniphila in inflammatory diseases |
| Akkermansia Muciniphila Supplement | Modulating microbial composition, for instance through fecal microbiota transplantation, has been shown to markedly attenuate colitis-associated inflammation in experimental models (). | 3 | Xie Luyu (2026) | Mechanism and application of Akkermansia muciniphila in inflammatory diseases |
| Akkermansia Muciniphila Supplement | Collectively, these findings indicate that preserving gut microbial balance is essential not only for controlling primary inflammatory disorders but also for slowing the progression of inflammation-associated conditions. | 3 | Xie Luyu (2026) | Mechanism and application of Akkermansia muciniphila in inflammatory diseases |
| Akkermansia Muciniphila Supplement | Park et al., 2023 Wang et al., 2023b Inflammation-related diseases encompass a range of pathological conditions driven by immune responses to either pathogens or to the body’s own tissues, representing a significant global health challenge. | 3 | Xie Luyu (2026) | Mechanism and application of Akkermansia muciniphila in inflammatory diseases |
Source documents